Teleflex launches next-generation Arrow™ VPS Rhythm™ DLX Device and NaviCurve™ Stylet in Canada
2024年10月23日 - 7:30PM
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies, today announced the launch of two new devices
in Canada designed to enhance PICC insertion procedures and reduce
the chance of complications. The next-generation Arrow™ VPS Rhythm™
DLX Device and NaviCurve™ Stylet are engineered to work together to
give Vascular Access professionals more efficient and predictable
PICC placement.
The next-generation VPS Rhythm™ DLX Device provides real-time
catheter tip location information by using the patient’s cardiac
electrical activity. The device is also available with an optional
integrated ultrasound featuring a Catheter-to-Vessel ratio tool
that promotes standardization in vessel measurement. This device
works in concert with the Arrow™ PICC preloaded with the NaviCurve™
Stylet, providing innovative tip navigation/location
technologies.
The VPS Rhythm™ DLX Device with TipTracker™ Technology
eliminates the need for a confirmatory x-ray when confirmation
checklist parameters are met, helping the clinician insert
seamlessly through ultrasound vessel assessment, PICC navigation,
to final tip confirmation in the lower third of the superior vena
cava (SVC).1
Due to the variability of patient vasculature, PICCs can
occasionally have difficulty advancing into the SVC on the first
attempt. The NaviCurve™ Stylet features an anatomical curve and
flexible tip that are designed to self-orient to patient anatomy
for enhanced PICC advancement into the SVC for successful
insertion.1
Teleflex conducted extensive research with industry-leading
Vascular Access professionals to design the enhancements featured
in the new VPS Rhythm™ DLX Device, NaviCurve™ Stylet, PICCS, and
other insertion accessories.
Clinician-inspired updates to the portfolio include:
- Integrated
ultrasound (optional) to assist
with vascular access
- Real-time
visual catheter
navigation, featuring a visualization area twice
the size of the BD Sherlock 3CG™2,3
- In benchtop testing, the
Arrow™ PICC preloaded with the NaviCurve™ Stylet achieved a 90%
drop rate into the lower third of the SVC in a simulated
model on the first insertion attempt. This is compared to
0% drop rate with market leading PICC from
BD1
- Premium
kit components available
including one-piece, full-body fenestrated drape, ultrasound probe
cover with gel, and 3M™ Tegaderm™ I.V. Advanced Securement
Dressing
“We remain committed to building strong partnerships with
clinicians and hospitals in Canada, and in delivering these latest
advancements in Arrow™ Catheter Insertion Technology from Teleflex
to align with our mutual goal toward zero catheter-related
complications. The introduction of our new positioning device and
enhanced catheter design complement our proprietary Arrowg+ard Blue
Advance™ PICC antimicrobial and antithrombogenic protection that
reduces thrombus accumulation and the primary pathogens responsible
for most healthcare associated infections.4 With critical
innovations and comprehensive education and bedside support, we are
well suited to be the partner of choice for our customers.” said
Lisa Kudlacz, President and General Manager, Teleflex’s Vascular
Access business unit.
About Teleflex IncorporatedAs a global provider
of medical technologies, Teleflex is driven by our purpose to
improve the health and quality of people’s lives. Through our
vision to become the most trusted partner in healthcare, we offer a
diverse portfolio with solutions in the therapy areas of
anesthesia, emergency medicine, interventional cardiology and
radiology, surgical, vascular access, and urology. We believe that
the potential of great people, purpose driven innovation, and
world-class products can shape the future direction of
healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™,
Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands
united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For
more information, please visit teleflex.com.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
References:
- Data on file: D041679 Benchtop Stylet Advancement in a
Simulated Use Anatomical Model of NaviCurve™ Product Stylet/PICC
Assemblies. Bench testing may not be indicative of clinical
performance.
- ADHX-001612: Design History File Index for VPS Rhythm® DLX
- SystemSherlock 3CG+Tip Confirmation System for use with
Site~Rite 8 Ultrasound System Instructions for Use, Page 24.
Available here:
https://www.bd.com/assets/documents/PDH/SiteRite-8/0749067_Sherlock-3CGIFU.pdf
- Antimicrobial – In vitro data on file 2010; AVER-004371,
AVER-004483, AVAR-000427. No correlation between in vitro/in vivo
testing methods and clinical outcomes have currently been
ascertained. Antithrombogenic ‐ As compared to uncoated PICCs,
intravascular ovine model inoculated with Staph aureus:
AVAR‐000427. No correlation between in vitro/in vivo testing
methods and clinical outcomes have currently been ascertained.
Rx only.
Contraindication:
Clinical assessment of the patient must be completed to ensure
no contraindications exist. The Arrowg+ard Blue Advance™ PICC is
contraindicated in the following areas:
- Patients with known hypersensitivity to chlorhexidine
- In presence of device related infections
- In presence of previous or current thrombosis in the intended
vessel or along the catheterized vessel pathway.
No correlation between in vitro/in vivo testing methods and
clinical outcomes have currently been ascertained.
3M and Tegaderm are registered trademarks of 3M or its
affiliates.
Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Advance,
Barrigel, Deknatel, LMA, NaviCurve, Pilling, QuikClot, Rüsch,
TipTracker, UroLift, VPS Rhythm, and Weck and are trademarks or
registered trademarks of Teleflex Incorporated or its affiliates,
in the U.S. and/or other countries. © 2024 Teleflex Incorporated.
All rights reserved. MC-009942
Contacts:TeleflexLawrence KeuschVice President,
Investor Relations and Strategy
Developmentinvestor.relations@teleflex.com610-948-2836
Teleflex (NYSE:TFX)
過去 株価チャート
から 10 2024 まで 11 2024
Teleflex (NYSE:TFX)
過去 株価チャート
から 11 2023 まで 11 2024